A 53-year-old woman who had suffered from severe rheumatoid arthritis developed pulmonary hypertension. Her small arteries in the lung showed plexogenic arteriopathy with fibrous intimal hyperplasia. There was also vasculitis of the small arteries in other organs and mural thrombosis in the pulmonary stem and abdominal aorta. The plexogenic arteriopathy which was responsible for pulmonary hypertension appears to be the result of vasculitis in association with rheumatoid arthritis.
I
t is well known that collagen disease is associated with vasculitis, 1 but pulmonary vasculitis in association with rheumatoid arthritis (RA) is rare.
We report a case of pulmonary hypertension which is attributed to pulmonary vasculitis with RA.
CASE REPORT
A 53-year-old woman with 19-year history of RA was admitted to hospital for cough and anasarca. Heart rate was 68 beats per minute and regular. Blood pressure was 124/90 mm Hg. Jugular veins were markedly dilated. Parasternal heave was present and the pulmonary second sound was palpably accentuated. Holosystolic murmur (grade 2/6) was heard on the lower left sternal border. Marked edema of both upper and lower extremities was present. Her hands and feet had the classic, advanced deformities of RA. The chest x-ray films and cardiac series showed cardiomegaly with right ventricular enlargement. The main pulmonary artery and its main branches were enlarged with pronounced peripheral attenuation. The ECG exhibited right ventricular hypertrophy and right atrial enlargement. The echocardiogram also showed marked right ventricular enlargement and paradoxic movement of interventricular septum. At the pulmonic valve, depth of A wave was 1 mm, E-F slope 2 mm/s and maxima) opening slope 390 mm/s. Mid-systolic rapid semiclosure followed by reopening was seen. Perfusion lung scan using w Tc labeled macroaggregated albumin revealed no perfusion defect. The hand x-ray film showed osteoporosis, bony destruction, joint deformity, and ankylosis (Fig 1) .
Laboratory tests revealed positive RA test (+ 2), increased gammaglobulin, mainly of IgG component, positive LE-cell and LE-phenomenon, and positive antinuelear antibody. Arterial gas analysis showed mild respiratory alkalosis with pH of 7.48, Pcos of 26.7 mm Hg, and Po2 of 79.9 mm Hg, respectively.
According to the diagnostic criteria of the American Rheumatism Association, the case was diagnosed as "classical RA," and therapeutically classified as "stage 4" in progression, "class 4" in functional capacity, because of osteoporosis, destruction of the bone and cartilage, and deformity plus ankylosis of the joint.
Cough and anasarca improved by therapy with a diuretic, but she continued to complain of severe dyspnea. Therefore, digitalis and more diuretic medication were administered, but she died suddenly. Cardiac catheterization could not be performed. ; ATROVENT is not indicated in the initial treatment of acute episodes of bronchospasm where rapid response is required.
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The hand x-ray film shows osteoporosis, bony destruction, joint deformity, and ankylosis.
At necropsy, pleural spaces were totally obliterated by serofibrinous pleuritis. The lungs were congested and microscopically showed widespread obstructive lesions of the pulmonary vasculature, including intimal fibrous proliferation and plexiform lesions of small muscular arteries and arterioles. The plexiform lesions were associated with fibrinous microthrombi. Lymphocyte infiltration and destruction of the elastic lamina were seen (Fig 2) .
Mild fibrosis of the peribronchial region and the alveolar septa was also present. There was no evidence of rheumatoid pneumoconiosis or rheumatoid nodules.
The pericardium was adhesive due to serofibrinous pericarditis without effusion. The heart was enlarged, weighing 460 g. The dilated right ventricle was hypertrophied with a wall thickness of 7 mm. The tricuspid valve ring was also dilated. There was no congenital or valvular disease. At the left main pulmonary artery, there was a large organizing thrombus, measuring 1.5 cm in diameter and 6.5 cm in length. Moreover, other large thrombi were found in the abdominal aorta, and left external and internal iliac arteries. Lymphocyte infiltration was represented around the vasa vasorum of these arteries and aorta (Fig 3, left) .
The survey of the deep venous system of the legs revealed no thrombi.
The examination of the salivary glands revealed chronic inflammatory cell infiltration around the small arteries with intimal fibrous proliferation and medial hypertrophy (Fig 3, right) . patients. 12 We present a case of bilateral tympanic membrane rupture associated with CPAP.
CASE REPORT
A 49-year-old man was admitted with recurrent upper gastrointestinal bleeding. The patient was alert, and his examination was unremarkable. The tympanic membranes and auditory canals were normal. He had adequate arterial oxygenation while breathing supplemental oxygen at 4 L/min by nasal cannula.
Shortly after admission, the patient had profuse hematemesis associated with hypotension which was treated with intravenous (IV) blood and crystalloid administration, as well as intravenous administration of vasopressin. Approximately 30 minutes later, the patient was dyspneic, orthopneic, agitated, and vigorously coughing (blood pressure was 220/120 mm Hg). Fine rales were heard in the lung bases and arterial blood gas levels demonstrated moderate hypoxemia. The patient was given furosemide, morphine sulfate, and diazepam intravenously; pitressin was discontinued. The fractional inspired concentration of oxygen (FIos) was increased to 0.50 by face mask. The patient experienced progressive dyspnea. A self-inflating adult silicone bag-valve resuscitator with 2,600 ml reservoir (Laerdal) incorporating a 5 cmH20 Downs CPAP valve (Vital Signs) was connected to the exhalation port of the expiration divertor (Laerdal valving system designed to separate inhalation from exhalation, part number 85-05-00). This was attached to a Downs face mask (Life Designs Systems) with the exhalation port sealed and firmly applied to the patient's face. CPAP was continuously measured with a manometer. The patient was breathing spontaneously with CPAP (5 cm HjO) with occasional coughing until he was pharmacologically sedated. Assisted ventilation was begun with the CPAP bag-valvemask prior to oral-trachea] intubation for hypercapnia (pH-7.26; Pco2-48; PaOj-61; SaO2-0186; FIo2 presumed to be 1.00,15 L/min O, flow). A chest roentgenogram showed pulmonary edema. The patient improved. He was extubated the following day, and his pulmonary edema lessened over the next week.
Immediately after intubation, the patient was found to have 
